{
    "id": 19223,
    "fullName": "DLL3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "DLL3 positive indicates the presence of the DLL3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10683,
        "geneSymbol": "DLL3",
        "terms": [
            "DLL3",
            "SCDO1"
        ]
    },
    "variant": "positive",
    "createDate": "03/06/2016",
    "updateDate": "04/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6740,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rovalpituzumab Tesirine treatment in Dll3 positive lung small cell carcinoma patients resulted in an objective response in 18% (11/60) of patients, including ten patients with overexpression of Dll3, and stable disease in 35 patients (PMID: 27932068; NCT01901653).",
            "molecularProfile": {
                "id": 19630,
                "profileName": "DLL3 positive"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5803,
                    "pubMedId": null,
                    "title": "Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_162941.html"
                },
                {
                    "id": 10548,
                    "pubMedId": 27932068,
                    "title": "Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27932068"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16556,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Rovalpituzumab Tesirine (Rova-T) resulted in shrinkage of target nodal metastases and complete or partial response in non-target lesions in a patient with DLL3-positive neuroendocrine prostate cancer, and in preclincial experiments Rovalpituzumab Tesirine (Rova-T) inhibited tumor growth in DLL3-expressing patient-derived xenograft (PDX) models and cell line xenograft models of neuroendocrine prostate cancer (PMID: 30894499).",
            "molecularProfile": {
                "id": 19630,
                "profileName": "DLL3 positive"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14620,
                    "pubMedId": 30894499,
                    "title": "Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30894499"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19630,
            "profileName": "DLL3 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}